Turbobol 10mg/tab 100 Tabletten by Raw Pharma

Usage

1. Confirm baseline bloodwork.: Before the first Turbobol tablet, collect ALT, AST, LH, FSH, and total testosterone panels to establish reference values for the combined Turbobol-plus-SARM protocol.
2. Select your SARM partner.: Choose one SARM for the cycle — Ostarine for lean preservation, LGD-4033 for strength, or RAD-140 at a reduced Turbobol dose (10–20 mg daily) given its stronger HPG suppression profile.
3. Begin at the lowest effective Turbobol dose.: Start at 10–20 mg daily alongside the chosen SARM during weeks one and two; the 10 mg tablet format allows single-unit increments without cutting.
4. Split daily Turbobol across two administrations.: Take half the daily dose with breakfast and half with the pre-training meal to distribute plasma exposure without the need to split tablets.
5. Run mid-cycle monitoring.: At protocol week four, collect ALT, AST, and LH via immunoassay; use these values to decide whether to maintain, reduce, or discontinue the oral component ahead of the stack's close.
6. Execute PCT immediately post-cycle.: Initiate a SERM-based PCT (Nolvadex 20 mg daily for four to six weeks) within 72 hours of the final Turbobol tablet, extending the recovery window if LH suppression is deeper than a single-compound cycle would produce.

Warnings

Frequently asked questions

Can Chlordehydromethyltestosterone be combined with SARMs in the same cycle?

Yes — Chlordehydromethyltestosterone and SARMs operate through complementary mechanisms, with the oral anabolic supplying full androgen receptor agonism while the SARM contributes tissue-selective partial activation. This dual-pathway environment produces an anabolic signal broader than either compound generates alone. The non-aromatising profile of Chlordehydromethyltestosterone means no additional aromatase inhibitor is required when it replaces a testosterone base in the SARM stack.

Which SARM pairings are most documented alongside oral Chlordehydromethyltestosterone?

Practitioner-reported data most frequently cites Ostarine (MK-2866) at 20–25 mg daily combined with Turbobol at 20–30 mg daily for lean-mass preservation, and LGD-4033 at 5–10 mg daily alongside Turbobol at 20 mg daily for strength-focused cycles. RAD-140 combinations are reported at lower Turbobol doses — typically 10–20 mg daily — given RAD-140's comparatively stronger suppressive profile, which compounds HPG axis burden when added to an alkylated oral.

What bloodwork monitoring is essential when stacking Turbobol with a SARM?

ALT and AST panels at protocol weeks two and four are mandatory because the 17α-alkylated structure of Chlordehydromethyltestosterone imposes hepatic enzyme stress independently of the SARM, and cumulative LH and FSH suppression from both compounds requires quantification before PCT planning. An LH immunoassay collected at the final week of the stack determines whether a standard four-week SERM protocol is sufficient or whether extended recovery is needed given combined suppression depth.

Why is the 10 mg per tablet dose of Turbobol particularly useful in a SARM combination stack?

A SARM combination protocol involves multiple variables — SARM dose, SARM type, cycle duration — making stepwise oral anabolic adjustment essential rather than optional. The 10 mg per tablet format enables single-unit escalation or reduction without tablet splitting, which pharmacy compounding literature confirms introduces gravimetric error. This precision is especially relevant when the SARM component is adjusted mid-cycle and the Turbobol dose must be recalibrated proportionally to maintain a stable combined anabolic load.

Does Turbobol come in blister packs or a jar, and how does packaging affect dosing discretion?

Turbobol is supplied in a 100-tablet jar format, which is both compact and resealable — practical for split daily doses stored at a workstation or gym bag. The sealed jar format protects tablet integrity from humidity exposure better than open blister strips in tropical or high-humidity storage environments. Each intact 10 mg tablet requires no preparation or cutting, keeping administration straightforward and dosing consistent across the full 100-unit supply. (2) angle_used

Manufacturer

Raw Pharma's pharmaceutical team brings a formulation-science orientation to the Turbobol tablet line that is most visible at the API intake stage: incoming Chlordehydromethyltestosterone active pharmaceutical ingredient is reviewed by qualified personnel against a supplier certificate of conformity covering identity, purity, and synthesis-route documentation before it is cleared for blending. The scientific staff responsible for release decisions are trained to treat HPLC content-uniformity data — collected against a certified Chlordehydromethyltestosterone reference standard — as the definitive per-tablet API figure rather than a calculated estimate derived from blend homogeneity assumptions. This expertise-led approach extends to LAL endotoxin screening at the raw material stage, a sequencing decision made by the team to intercept contamination risk before it reaches the compression matrix rather than relying on finished-product testing as the sole safety gate. Staff competency in dissolution specification management and disintegration endpoint control is reflected in the consistency of the 10 mg tablet format across production batches — a consistency that practitioners using Turbobol in precision SARM-combination protocols depend on when titrating dose by single-tablet increments.